News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

GenSpera 2014 Biotechnology Industry Organization (BIO) International Presentation Available

6/30/2014 9:59:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN ANTONIO, June 30, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, California.

Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202.


  • G-202 Data in Hepatocellular (HCC) Patients (Ph I and Ph II)
  • All patients previously progressed on, or were intolerant of, sorafenib
  • Outstanding clinical safety profile
  • Well tolerated with easily managed and predictable side effects
  • No effect on bone marrow!
  • 80% of patients with stable disease (no tumor growth) at two months
  • 50% of patients with stable disease for >/= 4 months
  • Long-term disease stabilization (>/= 9 months) in 15% of patients
  • One patient remains on treatment > 22 months
  • End of bone pain in one patient with vertebral metastasis

The full BIO presentation is available for view at:

About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company's website: or follow us on Twitter @GenSperaNews.

About BIO
The 2014 BIO International Convention was held June 23-26 at the San Diego Convention Center in San Diego, California.

The BIO International Convention was hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.


Company: Craig Dionne, PhD, CEO
GenSpera, Inc. +1-210-479-8112

Investors: John Baldissera
BPC Financial Marketing: 800-368-1217

Media: 800-665-0411

SOURCE GenSpera, Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at

Related News

comments powered by Disqus